Chronic recurrent multifocal osteomyelitis: Clinical outcomes after more than five years of follow-up

• DOI: 10.1067/mpd.2002.126457
• Publication Date: 2002-10-09T21:24:11Z
• Authors: Adam M. Huber; Pei-Yoong Lam; Catherine M. Duffy; Rae S.M. Yeung; Michael Ditchfield; Dara Laxer; William G. Cole; H. Kerr Graham; Roger C. Allen; Ronald M. Laxer
• Keywords: Male; Canada; Adolescent; Biopsy; Anti-Inflammatory Agents, Non-Steroidal; Australia; Child Welfare; Osteomyelitis; Inflammatory Bowel Diseases; Severity of Illness Index; Anti-Bacterial Agents; 3. Good health; Cohort Studies; 03 medical and health sciences; 0302 clinical medicine; Recurrence; Child, Preschool; Chronic Disease; Quality of Life; Humans; Female; Child; Follow-Up Studies

To determine the clinical outcomes of children with chronic recurrent multifocal osteomyelitis (CRMO).Inception cohorts of children with CRMO were established at two tertiary pediatric centers. Outcome data were obtained through review of hospital charts, interview and examination of patients, and completion of questionnaires by patients.Of 45 eligible subjects, 23 (51%) were assessed. Median time since diagnosis was 13 years (range, 6-25). At evaluation, 6 (26%) had active disease; 18 (78%) had Health Assessment Questionnaire scores of 0 (no/minimal physical disability), and 5 had scores >0. Some impairment was seen in all domains of measurement of quality-of-life test, especially those concerning nonphysical aspects of health. Six (26%) subjects continued to have pain as a result of CRMO. Associated medical problems included arthritis in 6, sacroiliitis in 3, psoriasis in 5, recurrent pustular rashes in 2, and inflammatory bowel disease in 3.Long-term clinical outcomes for children with CRMO appear to be generally good, with most subjects having no evidence of disease activity or sequelae. However, a number of subjects had persistent disease and, therefore, remain at risk of physical and psychologic complications. Further research is required to identify patients at risk for persistent disease, and to determine therapies that may prevent morbidity.